Revolution Medicines Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
RVMD$200.15+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $288,432 | $696,148 |
| Marketable securities | 1,415,108 | 1,156,807 |
| Accounts receivable | — | 1,254 |
| Prepaid expenses and other current assets | 25,662 | 25,072 |
| Total current assets | 1,729,202 | 1,879,281 |
| Property and equipment, net | 23,697 | 22,865 |
| Operating lease right-of-use asset | 76,193 | 77,149 |
| Intangible assets, net | 57,472 | 57,739 |
| Goodwill | 14,608 | 14,608 |
| Restricted cash | 3,031 | 3,031 |
| Other noncurrent assets | 4,159 | 7,032 |
| Total assets | $1,908,362 | $2,061,705 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $32,379 | $61,788 |
| Accrued expenses and other current liabilities | 53,175 | 74,694 |
| Operating lease liability, current | 8,169 | 7,369 |
| Total current liabilities | 93,723 | 143,851 |
| Deferred tax liability | 3,115 | 3,115 |
| Operating lease liability, noncurrent | 79,860 | 80,575 |
| Warrant liabilities | 3,157 | 6,512 |
| Other noncurrent liabilities | 3,040 | 1,458 |
| Total liabilities | 182,895 | 235,511 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; none issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 170,473,067 and 170,234,594 shares issued as of March 31, 2024 and December 31, 2023, respectively; 164,913,014 and 164,674,594 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 16 | 16 |
| Additional paid-in capital | 2,980,360 | 2,963,342 |
| Accumulated other comprehensive income (loss) | (1,198) | 544 |
| Accumulated deficit | (1,253,711) | (1,137,708) |
| Total stockholders' equity | 1,725,467 | 1,826,194 |
| Total liabilities and stockholders' equity | $1,908,362 | $2,061,705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.